Ardelyx, Inc. — Q2 2015 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2015. Amounts below are in millions of dollars unless stated otherwise. Ardelyx is a clinical-stage biopharmaceutical company; it reported no product-sales revenue.
Financial performance and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Total revenue | $18.143 | $9.137 | $24.026 | $17.687 |
| Operating income | $9.056 | $2.751 | $5.566 | $2.287 |
| Net income | $9.007 | $3.753 | $5.505 | $0.682 |
| Research and development expense | $6.198 | $5.183 | $12.396 | $12.820 |
| General and administrative expense | $2.889 | $1.203 | $6.064 | $2.580 |
- Q2 licensing revenue was $17.727 million and collaborative development revenue was $0.416 million. For the first half, those amounts were $21.611 million and $2.415 million, respectively.
- Reported operating margins were approximately 50% for Q2 and 23% for the first half. These are not representative of recurring product economics: there were no product sales, and the results include a one-time accounting effect related to the AstraZeneca termination.
- Operating cash flow was negative $38.433 million in the first half, versus positive $22.874 million a year earlier. Investing cash outflow was $2.320 million; financing provided $75.001 million.
- Cash and cash equivalents were $141.534 million at June 30, up from $107.286 million at year-end 2014. Current assets were $143.923 million and current liabilities $5.546 million. Total liabilities were $5.928 million; the filing reports no credit facility or committed capital source.
- Accumulated deficit was $66.362 million. No income-tax provision was recorded. The filing says the company expects its existing capital to cover projected operating requirements for at least 12 months, while warning that assumptions may prove wrong.
Material changes and unusual items
- In June, Ardelyx terminated its tenapanor collaboration with AstraZeneca and regained the relevant NHE3 inhibitor rights. The company recognized $43.1 million of remaining deferred revenue on termination; it also recorded $15 million paid for the return of the licenses and a $10 million payment for R&D reimbursement and accelerated transfer of information and materials as reductions in licensing revenue. The timing and net presentation of these items materially affect reported revenue and earnings.
- Under the termination terms, Ardelyx may owe AstraZeneca future royalties of 10% of net sales of tenapanor or other NHE3 products and 20% of certain non-royalty revenue from a new partner; the specified payments are capped at $90 million in aggregate. AstraZeneca is also to supply clinical materials and drug substance/product for up to $10 million at transfer pricing.
- June’s equity financing generated approximately $77.8 million gross and $74.4 million net from 7.24 million common shares and warrants for approximately 2.17 million shares. The warrants have a $13.91 exercise price. A July shelf registration permits up to $200 million of securities, including an at-the-market program of up to $50 million of common stock.
- The first-half operating cash outflow was heavily affected by a $47.053 million decrease in deferred revenue. The reported accounting profit should therefore not be read as evidence of product-sales profitability or positive operating cash generation.
Outlook, management commentary, and risks
- Management expected to start a Phase 3 tenapanor program for IBS-C and a Phase 2b dosing-regimen trial for hyperphosphatemia in dialysis patients in Q4 2015. It expected a Phase 1 healthy-adult study of RDX022 for hyperkalemia in Q4 2015 and said a Phase 3 program could begin as early as the second half of 2016.
- Management expected unpartnered R&D spending to rise as it advanced tenapanor, RDX022, and earlier-stage programs. The filing cautions that clinical development costs, timing, outcomes, and future funding needs are uncertain.
- Key execution risks include transferring tenapanor’s clinical, regulatory, and manufacturing activities from AstraZeneca; securing sufficient clinical supply; and establishing third-party manufacturing. The company also depended on third parties for clinical trials and had no sales organization.
- In a tenapanor Phase 2b hyperphosphatemia study, the primary endpoint was met, but diarrhea and discontinuations due to diarrhea at the highest doses were higher than expected. Clinical efficacy, safety, regulatory approval, competition, and reimbursement remain significant risks.
- Sanofi held an option to license the NaP2b inhibitor program; Ardelyx could receive up to $196.75 million in future development, regulatory, and commercial milestones and tiered royalties if the program advances and is commercialized. Receipt is contingent on Sanofi’s actions.
- The company reported no material litigation and no material change in market-risk disclosures. Management said disclosure controls were effective; a new ERP system began use during Q2, with no materially affecting control change identified.
Important facts for investors to verify
- How much of reported licensing revenue and earnings reflects the AstraZeneca termination and deferred-revenue recognition, rather than recurring activity?
- Were the planned tenapanor and RDX022 clinical studies initiated on schedule, and what were the subsequent efficacy, safety, and enrollment results?
- Did the tenapanor manufacturing and information transfer proceed on time, and what supply costs or delays resulted?
- What are actual operating cash burn and cash runway as clinical spending increases, and will additional financing be needed?
- What future AstraZeneca royalties or partner-revenue payments may become payable, and will Sanofi exercise its option or advance the NaP2b program?
- How much dilution may arise from the 2015 share issuance, outstanding warrants, or use of the $200 million shelf and $50 million ATM facility?